This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
May 3, 2012 4:30 p.m. ET
Jennifer Williams – Investor Relations
John McLaughlin – President, CEO, Acting CFO
Caroline Krumel – Vice President of Finance
Charles Duncan – JMP Securities
Phil Nadeau – Cowen & Company
Adnan Butt – RBC Capital Markets
Good afternoon and welcome to PDL BioPharma’s First Quarter 2012 Earnings Conference Call. Today’s call is being recorded.
For opening remarks and introduction, I would now like to turn the call over to Jennifer Williams.
Please go ahead ma’am.
Hello and thank you all for joining us today. I’d like to first point out that there is a slide presentation associated with today’s earnings call and you’ll see that in the Investor Relations section of the PDL website which you’ll find at pdl.com.
Before we begin, let me remind you that the information we will cover today contains forward-looking statements regarding our financial performance and other matters, and our actual results may differ materially from those expressed or implied in the forward-looking statements.
Factors that may cause differences between current expectations and actual results are described in our filings with the Securities and Exchange Commission, copies of which may be obtained in the Investor Section on our website at pdl.com.
The forward-looking statements made during this conference call should be considered accurate only as of the date of this call, and although we may elect to update forward-looking statements from time-to-time in the future, we specifically disclaim any duty or obligation to do so, even as new information becomes available or other events occur in the future.